Prognostic Value of Access and Non-Access Sites Bleeding After Percutaneous Coronary Intervention

被引:53
作者
Ndrepepa, Gjin [1 ]
Neumann, Franz-Josef [2 ]
Richardt, Gert [3 ]
Schulz, Stefanie [1 ]
Toelg, Ralph [3 ]
Stoyanov, Kiril M. [1 ]
Gick, Michael [2 ]
Ibrahim, Tareq [4 ]
Fiedler, Katrin Anette [1 ]
Berger, Peter B.
Laugwitz, Karl-Ludwig [4 ,5 ]
Kastrati, Adnan [1 ,5 ]
机构
[1] Tech Univ Munich, Deutsch Herzzentrum Munchen, D-80636 Munich, Germany
[2] Univ Herzzentrum Freiburg Bad Krozingen, Freiburg, Germany
[3] Segeberger Kliniken, Herzzentrum, Bad Segeberg, Germany
[4] Tech Univ Munich, Med Klin Rechts Isar 1, D-80636 Munich, Germany
[5] DZHK German Ctr Cardiovasc Res, Munich, Germany
关键词
hemorrhage; mortality; percutaneous coronary intervention; UNFRACTIONATED HEPARIN; INVASIVE STRATEGY; CLINICAL-TRIAL; BIVALIRUDIN; IMPACT; ABCIXIMAB; OUTCOMES; MORTALITY; CATHETERIZATION; PRETREATMENT;
D O I
10.1161/CIRCINTERVENTIONS.113.000433
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Little is known about the impact of bleeding site on mortality after percutaneous coronary intervention. The aim of this study was to assess the impact of access and non-access site bleeding within 30 days after percutaneous coronary intervention on mortality. Methods and Results-This study represents a pooled patient-level analysis of 14 180 patients recruited in 7 randomized trials. Access and non-access site bleeding were assessed using the Bleeding Academic Research Consortium criteria. The primary outcome was 1-year mortality. Follow-up was complete in 97.5% of the patients. There were 414 deaths within the first year after percutaneous coronary intervention: 44 deaths among patients with access site bleeding, 60 deaths among patients with non-access site bleeding, and 310 deaths among patients without bleeding (Kaplan-Meier estimates of mortality, 4.5%, 10.0%, and 2.5%, respectively; adjusted hazard ratio, 1.72 [95% confidence interval, 1.19-2.47] for access site bleeding versus no bleeding; hazard ratio, 2.78 [2.00-3.86] for non-access site versus no bleeding). The inclusion of non-access site bleeding (the absolute and relative integrated discrimination improvement, 0.005 and 8.9%; P=0.031) but not of access site bleeding (the absolute and relative integrated discrimination improvement, 0.0015 and 2.7%; P=0.084) was associated with an improvement of the discriminatory power of multivariable model for mortality prediction. Conclusions-Both access and non-access site bleeding events occurring within 30 days of a percutaneous coronary intervention are independently associated with an increased risk of 1-year mortality. Non-access site bleeding is a stronger correlate of mortality than access site bleeding, and it improves the discriminatory power of models for mortality prediction.
引用
收藏
页码:354 / 361
页数:8
相关论文
共 30 条
[1]   Women, Bleeding, and Coronary Intervention [J].
Ahmed, Bina ;
Dauerman, Harold L. .
CIRCULATION, 2013, 127 (05) :641-649
[2]   Meta-Analysis Comparing Bivalirudin Versus Heparin Monotherapy on Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention [J].
Bertrand, Olivier F. ;
Jolly, Sanjit S. ;
Rao, Sunil V. ;
Patel, Tejas ;
Belle, Loic ;
Bernat, Ivo ;
Parodi, Guido ;
Costerousse, Olivier ;
Mann, Tift .
AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (04) :599-606
[3]   Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study [J].
Cayla, G. ;
Silvain, J. ;
Barthelemy, O. ;
'O Connor, S. ;
Payot, L. ;
Bellemain-Appaix, A. ;
Beygui, F. ;
Aout, M. ;
Collet, J-P ;
Vicaut, E. ;
Montalescot, G. .
HEART, 2011, 97 (11) :887-891
[4]   Bleeding Avoidance Strategies [J].
Dauerman, Harold L. ;
Rao, Sunil V. ;
Resnic, Frederic S. ;
Applegate, Robert J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (01) :1-10
[5]   Adverse impact of bleeding on prognosis in patients with acute coronary syndromes [J].
Eikelboom, John W. ;
Mehta, Shamir R. ;
Anand, Sonia S. ;
Xie, Changchun ;
Fox, Keith A. A. ;
Yusuf, Salim .
CIRCULATION, 2006, 114 (08) :774-782
[6]   Predictors and impact of major Hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial [J].
Feit, Frederick ;
Voeltz, Michele D. ;
Attubato, Michael J. ;
Lincoff, A. Michael ;
Chew, Derek P. ;
Bittl, John A. ;
Topol, Eric J. ;
Manoukian, Steven V. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (09) :1364-1369
[7]  
GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
[8]   Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial [J].
Hamon, Martial ;
Rasmussen, Lars H. ;
Manoukian, Steven V. ;
Cequier, Angel ;
Lincoff, A. Michael ;
Rupprecht, Hans-Juergen ;
Gersh, Bernard J. ;
Mann, Tift ;
Bertrand, Michel E. ;
Mehran, Roxana ;
Stone, Gregg W. .
EUROINTERVENTION, 2009, 5 (01) :115-120
[9]   A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries [J].
Hausleiter, J ;
Kastrati, A ;
Mehilli, J ;
Schühlen, H ;
Pache, J ;
Dotzer, F ;
Glatthor, C ;
Siebert, S ;
Dirschinger, J ;
Schömig, A .
JOURNAL OF INTERNAL MEDICINE, 2004, 256 (05) :388-397
[10]   Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment -: The ISAR-REACT 2 randomized trial [J].
Kastrati, A ;
Mehilli, J ;
Neumann, FJ ;
Dotzer, F ;
ten Berg, JN ;
Bollwein, H ;
Graf, I ;
Ibrahim, M ;
Pache, J ;
Seyfarth, M ;
Schühlen, H ;
Dirschinger, J ;
Berger, PB ;
Schömig, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (13) :1531-1538